{"filings":[{"id":581601,"accession_number":"0001193125-26-234379","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2026-05-21T20:01:07+00:00","items":["5.07"],"status":"ready","headline":"Phathom stockholders elect three Class I directors, ratify EY, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Steven Basta, Theodore R. Schroeder, Mark Stenhouse as Class I directors: 42.7M, 42.6M, 41.2M votes for respectively.","Ratified Ernst & Young as independent auditor for FY 2026: 64.5M for, 49,661 against.","Advisory say-on-pay approved: 44.4M for, 2.5M against, 165,675 abstentions.","Broker non-votes of 17.5M on director election and say-on-pay; all proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95405,"accession_number":"0001193125-26-193945","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Pharma Q1 net rev $58.3M (+104% YoY); maintains FY 2026 op profitability guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenues $58.3M vs $28.5M YoY; net loss $30.4M vs $94.3M YoY.","Non-GAAP operating expenses $56.2M, down ~43% YoY; cash and equivalents $180.9M.","~1.35M total VOQUEZNA prescriptions filled to date; Q1 covered prescriptions up 91% YoY.","FY 2026 guidance: net rev $320-345M, non-GAAP op ex $235-255M; op profitability expected Q3 2026.","EoE phase 2 trial (pHalcon-EoE-201) topline results expected late Q4 2026/early Q1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":58301000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108465,"accession_number":"0001193125-26-073377","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom reports Q4 revenue $57.6M, FY2025 revenue $175.1M (+217% YoY); expects operating profitability in Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenues $57.6M; FY2025 net revenues $175.1M, a 217% increase over FY2024.","Q4 GAAP net loss narrowed to $21.1M from $74.5M in Q4 2024.","Non-GAAP adjusted net loss for Q4 was $5.7M, improved from $56.4M in Q4 2024.","Expects operating profitability beginning Q3 2026 and for FY2026; cash flow positivity in 2027.","Completed $130M equity offering Jan 2026; modified term loan to $175M principal, extended maturity to Feb 2029; pro forma cash ~$190M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":175110000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108464,"accession_number":"0001193125-26-007660","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phathom Pharmaceuticals prices $130M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["6,875,000 shares of common stock at $16.00/share and pre-funded warrants for 1,250,078 shares at $15.999/warrant.","Gross proceeds approximately $130M; underwriters have 30-day option for additional 1,218,761 shares.","Net proceeds for general corporate purposes, including working capital and R&D.","Offering expected to close on/about January 9, 2026; Guggenheim Securities and Cantor are joint bookrunners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108463,"accession_number":"0001193125-26-006266","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom reports preliminary Q4 2025 revenue $57-58M; full year $174.5-175.5M; VOQUEZNA surpasses 1M prescriptions","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net revenues expected ~$57-58M; full year 2025 net revenues ~$174.5-175.5M.","GAAP operating expenses Q4: ~$59-61M; non-GAAP (excl. stock-based comp) ~$51-53M.","Cash and equivalents ~$130M as of 12/31/25; net cash usage in Q4 ~$6M.","VOQUEZNA products surpassed 1 million prescriptions dispensed in U.S. during Q4.","Operating profitability (excl. stock-based comp) anticipated in second half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":175110000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124900,"accession_number":"0001193125-25-263534","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom Pharmaceuticals doses first patient in Phase 2 EoE trial of VOQUEZNA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 2 pHalcon EoE-201 trial evaluating VOQUEZNA (vonoprazan) for eosinophilic esophagitis in adults.","Part 1: 80 adults with confirmed EoE and dysphagia randomized 1:1 to VOQUEZNA 20 mg or placebo once daily for 12 weeks.","Part 2: open-label 12-week extension where all patients receive VOQUEZNA 20 mg daily.","Topline results from primary and secondary endpoints are anticipated in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124899,"accession_number":"0001193125-25-257382","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Q3 revenue $49.5M, up 25% QoQ; net loss $30M; FY guidance raised to $170-175M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue of $49.5M in Q3 2025, up 25% from Q2 and from $16.4M in Q3 2024.","Net loss narrowed to $30.0M from $85.6M in Q3 2024; non-GAAP adjusted net loss $11.2M.","Full-year 2025 revenue guidance raised to $170-175M; expects operating profitability in 2026.","Over 790,000 cumulative VOQUEZNA prescriptions filled; Q3 filled prescriptions up 28% QoQ.","Appointed Sanjeev Narula as CFO/Chief Business Officer and Nancy Phelan as SVP Marketing."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":117526000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124898,"accession_number":"0001193125-25-250611","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom publishes Phase 3 NERD data showing VOQUEZNA improves nocturnal GERD symptoms","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At week 4, VOQUEZNA 10 mg and 20 mg achieved 59.9% and 56.4% heartburn-free nights vs 43.3% placebo (nominal p<0.0001).","Median heartburn-free nights: 70.4% (10 mg), 71.0% (20 mg), 45.5% (placebo) over 4 weeks.","Separation from placebo observed after first dose: 45.3% (10 mg) and 52.4% (20 mg) heartburn-free night vs 32.1% placebo.","Symptom relief sustained through 20-week active extension; median heartburn-free nights remained above 70%.","VOQUEZNA generally well tolerated; most common AEs (≤5%) included URI, sinusitis, influenza, UTI, nausea."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124897,"accession_number":"0001193125-25-230984","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Phathom Pharmaceuticals appoints Sanjeev Narula as CFO and Business Officer effective Oct 6, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sanjeev Narula named Chief Financial and Business Officer; replaces Robert Breedlove as principal financial officer.","Initial base salary of $550,000 with annual target bonus of 50% of base salary.","Receives stock options for 200,000 shares (4-year vest) and 144,000 RSUs (3-year annual vest).","Narula previously CFO of Intra-Cellular Therapies and Viatris; brings extensive biopharma finance experience.","Robert Breedlove continues as Vice President, Finance and principal accounting officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141612,"accession_number":"0001193125-25-174943","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Q2 revenue $39.5M, up from $7.3M YoY; 580k+ VOQUEZNA scripts filled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $39.5M in Q2 2025 vs $7.3M in Q2 2024; net loss $75.8M vs $91.4M YoY.","Over 580k total VOQUEZNA prescriptions filled (+49% since May 1); ~173k in Q2 (36% sequential growth).","10-year NCE exclusivity for VOQUEZNA 10mg/20mg tablets through May 2032; generic entry unlikely before 2033.","Full-year 2025 revenue guidance $165M-$175M; expects non-GAAP OpEx <$60M in Q3 and <$55M in Q4.","Appointed Anne Marie Cook as Chief Legal Officer and Corporate Secretary."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":68023000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159485,"accession_number":"0001193125-25-141119","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA Orange Book corrected; VOQUEZNA NCE exclusivity confirmed through May 2032","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA updated Orange Book to show full 10-year NCE exclusivity for VOQUEZNA (vonoprazan) 10 mg and 20 mg tablets.","Corrected listing confirms exclusivity runs through May 3, 2032, aligning with statutory requirements.","Phathom says this reinforces the long-term commercial runway for its first-in-class product.","NCE exclusivity prevents generic competition for the full 10-year period from approval date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159484,"accession_number":"0001193125-25-137800","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PHAT shareholders elect two directors, ratify EY, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Heidi Kunz elected Class III director with 34,023,182 for, 451,384 withheld; James Topper with 26,884,171 for, 7,590,395 withheld.","Ernst & Young LLP ratified as auditor for fiscal 2025: 51,670,346 for, 177,785 against, 53,817 abstentions.","Say-on-pay approved on non-binding advisory basis: 24,584,781 for, 8,704,739 against, 1,185,046 abstentions, 17,427,382 broker non-votes.","Say-on-frequency set to every 1 year with 30,665,967 votes for, 21,543 for 2 years, 2,611,188 for 3 years, 1,175,868 abstentions.","Company will hold annual advisory votes on executive compensation until next required say-on-pay vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159483,"accession_number":"0001193125-25-137094","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA grants Phathom citizen petition; VOQUEZNA exclusivity extended to May 2032","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Phathom's 2024 citizen petition to correct Orange Book for VOQUEZNA (vonoprazan) tablets.","VOQUEZNA will benefit from the 10-year NCE*GAIN exclusivity originally awarded to VOQUEZNA Triple Pak and Dual Pak.","FDA will update Orange Book to reflect exclusivity extending through May 3, 2032 (previously May 3, 2027).","Decision protects VOQUEZNA from generic competition for an additional 5 years under FDA's umbrella policy.","VOQUEZNA was not itself designated as a QIDP, but the exclusivity attaches to the active moiety vonoprazan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159482,"accession_number":"0001193125-25-108726","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Q1 net revenue $28.5M, net loss $94.3M; cuts costs, exec changes, targets 2026 profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $28.5M (up from $1.9M YoY); net loss $94.3M ($77.1M non-GAAP adjusted).","Over 390k VOQUEZNA prescriptions filled; ~127k in Q1, up ~8% sequentially despite seasonal headwinds.","Cost reduction: cut 2025 opex by $60-70M, reduce headcount ~6%, pause EoE trial, target Q4 spend <$55M.","CEO restructuring: new SVP Sales from Intra-Cellular; COO, CCO, CFO exit; Ted Schroeder on Board.","Citizen Petition filed Dec 2024 for 10-year NCE exclusivity; FDA response due within 180 days."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":28519000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159481,"accession_number":"0001193125-25-082089","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Phathom Pharmaceuticals appoints Theodore R. Schroeder to board, effective April 16, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Schroeder appointed as Class I director, term expiring at 2026 annual meeting; will serve on audit committee.","Received option for 35,000 shares and 21,000 RSUs, both vesting over three years; plus cash compensation.","Former CEO of Nabriva Therapeutics, co-founded Cadence Pharmaceuticals (bought by Mallinckrodt), held senior roles at Elan, Dura, and Bristol-Myers Squibb.","Board determined Schroeder meets Nasdaq independence standards; no related party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159480,"accession_number":"0001193125-25-069748","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CEO transition at Phathom: Steven Basta appointed, Terrie Curran resigns effective March 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Basta appointed CEO, President and Class I director effective April 1, 2025; Terrie Curran resigned for personal reasons.","Basta receives $700k base salary, 70% target bonus, and initial option grant of 1,085,000 shares vesting over 4 years.","Basta also granted 360k stock-price-hurdle PSUs and 180k revenue-based PSUs (target) under new inducement plan.","Curran severance includes base salary through June 30, 2026, 2025 target bonus lump sum, COBRA, and accelerated vesting.","Board adopted 2025 Employment Inducement Incentive Award Plan reserving 2,500,000 shares without stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177861,"accession_number":"0001193125-25-047882","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Pharma Q4 revenue $29.7M; VOQUEZNA prescriptions up 81% QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 net revenue $55.3M from VOQUEZNA launch; Q4 revenue $29.7M (81% increase vs Q3).","Over 300,000 filled prescriptions launch-to-date, up ~110% since last earnings report.","Q4 net loss $74.5M; non-GAAP adjusted net loss $56.4M vs $46.0M in prior year Q4.","SG&A expenses rose to $290.7M in FY2024 vs $117.9M in FY2023 due to commercial buildout.","Phase 2 EoE trial for VOQUEZNA to begin enrollment in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194570,"accession_number":"0001193125-24-274876","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom files Citizen Petition to correct VOQUEZNA Orange Book exclusivity to May 2032","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Petition requests FDA correct VOQUEZNA tablet listings to reflect 10-year NCE exclusivity ending May 3, 2032.","Exclusivity stems from GAIN Act extension on vonoprazan, already applied to VOQUEZNA DUAL/TRIPLE PAK approved May 2022.","FDA must respond within 180 days; may approve, deny, or provide tentative response.","Corrected listing would block ANDA or 505(b)(2) submissions referencing vonoprazan until expiry.","Phathom expects CP docket to appear on regulations.gov in coming days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194569,"accession_number":"0001193125-24-252642","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Q3 net revenues $16.4M, up >120% QoQ; net loss $85.6M; VOQUEZNA prescriptions exceed 143k launch-to-date","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $16.4M for Q3 2024 (vs $7.3M Q2 2024); no revenues in Q3 2023.","Over 143,000 prescriptions for VOQUEZNA products filled launch-to-date (138% increase since last quarterly report).","Net loss $85.6M vs $43.2M in Q3 2023; non-GAAP adjusted net loss $67.9M vs $30.8M.","Commercial access expanded to >80% of U.S. commercial lives (est. 120M covered lives).","R&D expenses down to $8.7M; SG&A up to $76.1M due to commercial buildout."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":25588000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210893,"accession_number":"0001193125-24-202879","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phathom Pharmaceuticals prices $130M stock/warrant offering; net proceeds ~$121.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["8,695,652 shares at $11.50/share and pre-funded warrants for 2,608,922 shares at $11.499/warrant.","Gross proceeds ~$130M; net proceeds ~$121.7M after underwriting discounts and expenses.","Offering expected to close August 20, 2024; use proceeds for commercialization and vonoprazan clinical development.","Joint bookrunners: Evercore ISI, Stifel, Guggenheim; co-managers: H.C. Wainwright, Needham, Craig-Hallum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210892,"accession_number":"0001193125-24-196506","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Q2 revenue $7.3M, prescriptions up 184%; VOQUEZNA gets FDA approval for Non-Erosive GERD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $7.3M in Q2 2024 vs $1.9M in Q1 2024; no Q2 2023 revenue due to launch in late 2023.","Over 122,000 cumulative prescriptions written (184% increase from 43,000); over 60,000 filled (240% from 17,500).","FDA approved VOQUEZNA 10mg for Non-Erosive GERD on July 18; commercial coverage now >116M lives (77% of US commercial).","Net loss $91.4M; non-GAAP adjusted net loss $73.3M; SG&A rose to $75.9M on launch commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":9236000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210891,"accession_number":"0001193125-24-180750","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom gets FDA approval for VOQUEZNA to treat heartburn in Non-Erosive GERD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved VOQUEZNA (vonoprazan) 10 mg tablets for relief of heartburn associated with Non-Erosive GERD in adults.","This is the third FDA approval for VOQUEZNA; also approved for Erosive GERD and H. pylori eradication.","Approximately 45 million US adults have Non-Erosive GERD; about 15 million treated with prescription medicine annually.","Non-Erosive GERD is the largest GERD category, characterized by reflux symptoms without esophageal erosions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229316,"accession_number":"0001193125-24-147017","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Phathom stockholders elect three Class II directors; ratify E&Y as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Cola (24.1M for), Karbe (25.0M for), Parikh (21.3M for) with 10.8M broker non-votes each.","Ratified Ernst & Young as independent auditor for fiscal 2024: 37.9M for, 124.6K against, 1.1K abstain.","New non-employee directors get initial grant of 21,000 RSUs and options to purchase 35,000 shares.","Annual director equity grant set at 10,500 RSUs and options for 17,500 shares; cash retainers unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229315,"accession_number":"0001193125-24-134793","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom posts Q1 net loss $82.9M, revenue $1.9M; VOQUEZNA prescriptions top 17,500","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss GAAP $82.9M (non-GAAP adj. net loss $64.8M) vs $37.8M loss Q1 2023; revenue $1.9M from VOQUEZNA launch.","Over 17,500 prescriptions dispensed launch-to-date (+361% vs last quarterly report); >3,800 prescribers.","SG&A expenses $62.0M (up from $18.6M YoY) reflecting commercial infrastructure build and marketing.","Cigna added VOQUEZNA to formularies; commercial coverage now ~48% of U.S. commercial lives (~72M covered).","FDA PDUFA date July 19, 2024 for NERD indication; Phase 3 NERD and Phase 2 EoE studies planned later in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":1912000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}